Featured News

After years of advocacy emphasizing the lack of kidney cancer federal funding, on Tuesday, May 17th, the House Appropriations Committee approved the FY17 Defense Appropriations Act and forwarded the bill to the full House.  The fiscal year 2017 Defense appropriations bill includes a $10 million line item within the Defense Health Program, Congressional Directed Medical Research Program for kidney cancer research. This is great news for the kidney cancer community. If this legislation is enacted,… More →



13 Must-Read Books for Oncologists

by Jay Bitkower on January 7, 2016

The following books were recommended for reading to oncologists by the editors of the oncology journal, Cancer Network. Happy reading!  



ACKC Action Pays Off in Congress Budget Deal

by Jay Bitkower on December 19, 2015

Congress highlights need for National Cancer Institute to increase attention to kidney cancer research and its early detection efforts. Yesterday (December 18, 2015), Congress passed the $1.8 trillion omnibus appropriation bill for Fiscal Year 2016 (October 1, 2015 – September 30, 2016). The bill calls for an increase of $2 billion in the NIH budged and $264 million in the National Cancer Institute’s budget, bringing the latter to $5.2 billion. This is good news considering… More →



DoD Award for Enhancing Immune Checkpoint Inhibitors

by Jay Bitkower on October 19, 2015

  Hans Hammers from Johns Hopkins Cancer Center won an Idea Award from the Department of Defense for Fiscal Year 2014 for “Enhancing Immune Checkpoint Inhibitor[1] Therapy in Kidney Cancer”. This is a two-year grant in the amount of $486,000 awarded to Dr. Hammers and Johns Hopkins. DoD grants have normally gone to pure researchers, but Dr. Hammers, aside from doing research, is also an eminent clinical oncologist who has made a number of presentations… More →



Exelixis Announces Start of Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — Jul. 13, 2015 — Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of a phase 1 trial of cabozantinib in combination with nivolumab alone or in combination with nivolumab plus ipilimumab in patients with advanced/metastatic urothelial (bladder) and other genitourinary tumors…. More →